RELATED Live.
Global ‘HeartMate 3 Center of Excellence’ demonstrates its capabilities and expands its capacity for treating severe cases
From bridge to transplant to permanent therapy — broadening the options for patients with end-stage heart failure

The Heart Failure Team of the Cardio-Cerebrovascular Hospital at Seoul St. Mary’s Hospital, The Catholic University of Korea, held a ceremony on November 10 to mark its cumulative 50th implantation of the HeartMate 3, the latest left ventricular assist device (LVAD).
LVAD implantation is a highly complex operation in which a mechanical device is implanted in the left ventricle of a patient with end-stage heart failure whose cardiac pumping function has declined, in order to support blood circulation throughout the body. The procedure is performed after a multifaceted evaluation of the patient’s cardiac function, overall condition, and comorbidities.
For patients waiting for a heart transplant, the device serves as a bridge that supports cardiac function until transplantation. For patients for whom transplantation is difficult because of advanced age or underlying disease, it is used as a permanent treatment alternative.
The HeartMate 3, the latest third-generation LVAD, is a fully magnetically levitated centrifugal blood pump in which the rotor spins while suspended by magnetic force. Because it has no mechanical bearings, friction is low, and because the blood flow pathways are wide, the shear stress applied to blood cells is low, so hemolysis is known to be relatively infrequent.
In a randomized clinical trial conducted overseas, the device was reported to be relatively superior in terms of survival free of stroke, bleeding complications, and reoperation to replace or remove the pump. Based on this safety profile, Seoul St. Mary’s Hospital introduced the HeartMate 3 in July 2021, and the Heart Failure Team has applied the device according to each patient’s condition within a multidisciplinary care system.
To perform this highly complex surgery safely and maximize the effect of patient-tailored treatment, the Cardio-Cerebrovascular Hospital operates a multidisciplinary care system centered on the Department of Cardiology and the Department of Thoracic and Cardiovascular Surgery. Various departments, including Neurology, Radiology, Anesthesiology and Pain Medicine, and Pathology, as well as dedicated nurses, dietitians, rehabilitation therapists, and pharmacists, take part in regular consultations and meetings and closely and precisely manage the entire process from diagnosis to surgery and recovery. The skilled technique of the medical staff and the close cooperation of the Heart Failure Team are regarded as key factors in raising the treatment success rate.
The ceremony began with a prayer of blessing by Fr. Hee-Jun Shin, Vice President for Spiritual Affairs. It was attended by key hospital leaders, including Chang-Ki Min, Executive Vice President for Medical Affairs of The Catholic University of Korea and President of the Catholic Medical Center; Ji Youl Lee, President of Seoul St. Mary’s Hospital; Seung-Ki Kwak, Vice President for Medical Affairs of Seoul St. Mary’s Hospital; Fr. Ye-Won Choi, Vice President for Administration; Woo-Baek Chung, Director of the Cardio-Cerebrovascular Hospital at Seoul St. Mary’s Hospital; and Hye-Kyung Kim, Vice President for Nursing, together with faculty and staff of the Cardio-Cerebrovascular Hospital and guests including Sang-Jin Park, President of Abbott Medical Korea, and Hee-Jin Yoon, Director of BT PLUS. They celebrated the achievement and shared the current status of the Heart Failure Team and its vision for future development.
“This record of 50 cases is not a mere number. It is the fruit of the dedication of the Heart Failure Team, which has given new life and hope to critically ill patients, and of Seoul St. Mary’s Hospital’s philosophy of respect for life,” said Chang-Ki Min, Executive Vice President for Medical Affairs of The Catholic University of Korea and President of the Catholic Medical Center. “The Catholic Medical Center will continue to do its utmost and spare no support for the development and expansion of the heart failure field.”
“Reaching 50 cases of third-generation LVAD implantation goes beyond a simple figure. It is a valuable result achieved through close cooperation among many departments and professions,” said Woo-Baek Chung, Director of the Cardio-Cerebrovascular Hospital at Seoul St. Mary’s Hospital. “We will further raise our expertise in the heart failure field by continuing our research and strengthening our clinical capabilities.”
Meanwhile, in September 2023, the Cardio-Cerebrovascular Hospital at Seoul St. Mary’s Hospital was officially designated a ‘HeartMate 3 Center of Excellence’ by the global medical device company Abbott in recognition of its excellent clinical outcomes and exemplary patient management process. In addition to reaching 50 third-generation LVAD implantations, the Heart Failure Team has performed a total of 15 heart transplants in the approximately 10 months from January 2026 to the present, continuing its achievements in the treatment of severe and end-stage heart failure.
Source: Hospital Newspaper , November 11, 2026
RELATED Live.
RELATED Doctor
RELATED Members
Inquiry